Use of cetuximab in patients with colon and rectal metastatic cancer.
Uso de cetuximab en cáncer de colon y recto metastásico.
Article Sidebar
PDF (Español (España))
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Main Article Content
Objective: To describe the clinical characteristics and outcomes in patients with metastatic colorectal cancer treated with cetuximab in the INC (Bogotá, Colombia). Methods: 49 clinical records of patients treated between January 2008 and July 2014 were analyzed. Descriptive analysis was performed. Results: Most patients were female (59%), the average age was 58.7 years, the predominant histology was adenocarcinoma usual and unspecified (78%), moderately differentiated (51%) with rectum (33%) and sigmoid (20%) as predominant primaries. Of the 49 patients included, the status of the non-mutated KRAS gene was confirmed in 48 of them and in one of them was not known. Cetuximab therapy was used mostly as second or higher metastatic line. The most common scheme accompanying chemotherapy was Folfiri (61%). The causes of discontinuation were disease progression (37%), and adverse effects (33%). The most common were rash (61%), fatigue (42%) and gastrointestinal (40%). The median time to progression was 8.4 months and the median overall survival was 14.4 months. Conclusion: We present the experience for six years with monoclonal anti-EGFR (cetuximab) in patients with metastatic colorectal cancer in the major referral center for cancer treatment in the country. Differences in this selected population including female predominance, distal location of the primary tumor and a slightly better overall survival when used in left-sided tumors, in the first line and associated with regimens including irinotecan.
Downloads
Article Details
Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide; 2012. International Agency for Research on Cancer. World Health Organization. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30.
Piñeros M, Pardo C, Gamboa O, Hernández G. Atlas de mortalidad por cáncer en Colombia. 3ª ed. Bogotá: República de Colombia, Ministerio de la Protección Social, Instituto Nacional de Cancerología ESE, Instituto Geográfico Agustín Codazzi (IGAC); 2010.
Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw 2009;7(8):838-81.
Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 2012;18(37):5171-80.
De Stefano A, Carlomagno C. Beyond KRAS: predictive factors of the efficacy of anti-EGFR monoclonal antiboides in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20(29):9732-43.
Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Ann Oncol 2015;26(1):13-21.
Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol 2015;33(7):682-5.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8.
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7):1535-46.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17.
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-9.
Jonker DJ, Karapetis C, Harbison C, et al. High epiregulin (EREG) gene expression plus K-RAS wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from NCIC CTG CO.17--a phase III trial of cetuximab versus best supportive care (BSC). Program and abstracts of the 2009 in: Annual Meeting of the American Society of Clinical Oncology. 2009; Orlando, Florida. Abstract 4016.
Adam R. Developing strategies for liver metastases from colorectal cancer. Semin Oncol 2007;34(2 Suppl 1):S7-11.
Marshall JL. Managing potentially resectable metastatic colon cancer. Gastrointest Cancer Res 2008;2(4 Suppl):S23-6.
Rubiano JA, Garrido A, Castillo JS. Uso de bevacizumab en pacientes con cáncer de colon metastásico en el Instituto Nacional de Cancerología: una serie de casos. Rev Colomb Cancerol 2012;16(4):227-33.
National Comprehensive Cancer Network. Colon cancer (version 1.2016). [citado 2016 ene 6]. Disponible en: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
Salgado A, Carrillo S, Farfán Y, Olaya N, Serrano G, Mesa J. Detección de mutaciones en el gen KRAS en tejido FFEP en pacientes con adenocarcinoma colorrectal avanzado en el INC. Rev Colomb Cancerol 2013;17(4):187-8.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783):2103-14.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, VehlingKaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065-75.
Cardona A, Vargas C, Carranza H, et al. Carta al editor. Uso de bevacizumab en pacientes con cáncer de colon metastásico en el Instituto Nacional de Cancerología: una serie de casos. Rev Colomb Cancerol 2013;17(2):53-4.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45.
Ciardiello F, Normann N, Martinelli E, Troiani T, Cardone C, Nappi A, et al. Cetuximab beyond progression in RAS wild type (WT) CAPRI-GOIM. Ann Oncol 2015;26(suppl 4): IV120-21.
Venook A, Niedzwiecki D, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progressionfree survival (PFS) in patients (PTS) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016;34(suppl): abstract 3504.
Venook A, Niedzwicki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results (abstract). J Clin Oncol 2006; 24:148s.
